Ashurst has advised UBS and DBS in connection with the US$180 million Hong Kong initial public offering of China Pioneer Pharma Holdings Limited. Pioneer Pharma is a leading marketing and promotion services provider for imported pharmaceutical products with a distribution network that covers over 7,500 hospitals and 40,000 drugstores in China.

UBS acted as sole global coordinator and sole sponsor in connection with the transaction, and UBS and DBS acted as joint bookrunners and joint lead managers.

The Ashurst team was led by Hong Kong partner Lina Lee, assisted by Tracy Li, Adrian Cheung and Naomi Hong. Partner Stuart Rubin led the US team, assisted by Li Jiang.

Commenting on the transaction, Lina Lee said:

"We are delighted to have assisted UBS and DBS on this transaction.  The IPO is our latest in a series of successful PRC healthcare transactions with UBS, and we are pleased that investment banks and corporates continue to call upon our expertise within the healthcare sector for both capital markets and M&A transactions."